Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infection

Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infection

Introduction: Direct-acting antivirals (DAAs) represent a breakthrough in hepatitis C virus (HCV) treatment as they directly inhibit HCV nonstructural (NS) proteins (NS3/4A, NS5A, and NS5B). However, ongoing debates exist regarding their relationship with hepatocellular carcinoma (HCC) whose inciden...

Full description

Bibliographic Details
Main Authors:	Ahmad M. Zidan, Eman A. Saad, Nasser E. Ibrahim, Medhat H. Hashem, Amal Mahmoud, Alaa A. Hemeida
Format:	Article
Language:	English
Published:	Elsevier 2021-05-01
Series:	Heliyon
Subjects:	Pharmacogenomics PHARMIP HCV direct-Acting antivirals Hepatocellular carcinoma Personalized medicine HCV
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844021010112

Similar Items

Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district
by: Polilli E, et al.
Published: (2016-09-01)

Cost-effectiveness analysis with direct-acting antivirals in a cohort of HCV-infected inmates in Italy
by: Roberto Ravasio, et al.
Published: (2020-12-01)

Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients
by: Soraya Abad, et al.
Published: (2017-03-01)

Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland
by: Karoline Aebi-Popp, et al.
Published: (2016-01-01)

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
by: Sara Kishta, et al.
Published: (2020-06-01)

Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
by: Leonardo Frazzoni, et al.
Published: (2021-04-01)

Hepatitis C core antigen: a simple predictive marker for treatment response to the new direct-acting antiviral drugs in chronic HCV Egyptian patients
by: Asmaa M. Elbrolosy, et al.
Published: (2021-03-01)

Molecular Study of Occult Hepatitis C Infection among Iranian Hemophilia Patients Treated with Direct-acting Antiviral Agents
by: Elnaz Agi, et al.
Published: (2020-01-01)

Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma
by: Catia Giovannini, et al.
Published: (2020-09-01)

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics
by: Luca Rinaldi, et al.
Published: (2020-05-01)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
by: Andrea Angeletti, et al.
Published: (2019-02-01)

SVR 24 Achievement Two Weeks After a Tripled Dose of Daclatasvir in an HCV Genotype 3 Patient
by: Sara Lo Menzo, et al.
Published: (2018-07-01)

Interactions between Immunosuppressive Therapy and Direct-Acting Antivirals in Kidney Transplant Recipient with Hepatitis C Infection
by: Paolo Carta, et al.
Published: (2020-05-01)

CONCORDANCE OF NON-INVASIVE TESTS FOR LIVER FIBROSIS IN HCV PATIENTS PROPOSED FOR TREATMENT WITH DIRECT ACTING ANTIVIRALS
by: Andreea Cazan, et al.
Published: (2018-09-01)

Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care
by: Leen Delang, et al.
Published: (2010-03-01)

Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study
by: Luca Rinaldi, et al.
Published: (2019-08-01)

Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets
by: Nathalie Alazard-Dany, et al.
Published: (2019-01-01)

HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study
by: Curtis L. Cooper, et al.
Published: (2019-08-01)

A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome
by: Sabrina Bagaglio, et al.
Published: (2020-02-01)

Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8+ T-Cells in Advanced Liver Disease
by: Agatha Vranjkovic, et al.
Published: (2019-08-01)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
by: Andrew Hill, et al.
Published: (2018-04-01)

Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report
by: Michiko Shimada, et al.
Published: (2017-03-01)

The distribution of hepatitis C virus genotypes in patients with hepatocellular carcinoma
by: Ayfer Bakır, et al.
Published: (2019-10-01)

Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis
by: Liwei Zhuang, et al.
Published: (2021-07-01)

Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment
by: Jennifer J. Lin, et al.
Published: (2021-11-01)

Evaluation of direct-acting antivirals and antiretroviral therapy for HIV-HCV coinfected patients in the United States
by: Rivera, Josef Kyle Concepcion
Published: (2021)

Virologic Tools for HCV Drug Resistance Testing
by: Slim Fourati, et al.
Published: (2015-12-01)

Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype
by: von Massow G, et al.
Published: (2019-04-01)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience
by: Hassan AM, et al.
Published: (2018-06-01)

Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1–6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance
by: Lize Cuypers, et al.
Published: (2015-09-01)

Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs
by: Stefania Paolucci, et al.
Published: (2020-02-01)

Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China
by: Jian Zhang, et al.
Published: (2019-07-01)

New therapies on the horizon for hepatitis C
by: Silvia C Sookoian, MD
Published: (2003-10-01)

Review of Antiviral Effects of Glycyrrhiza glabra L. and Its Active Component, Glycyrrhizin
by: M Nassiri Asl, et al.
Published: (2007-05-01)

Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort
by: Bernuth S, et al.
Published: (2017-07-01)

Pharmacotherapy Profiles in People with Opioid Use Disorders: Considerations for Relevant Drug–Drug Interactions with Antiviral Treatments for Hepatitis C
by: Andreas Hintz, et al.
Published: (2021-05-01)

Mechanistic Insights into Translation and Replication of Hepatitis C Virus RNA : Exploring Direct-Acting Antivirals
by: Kumar, Anuj
Published: (2018)

Impact of Sustained Viral Response in the Evolution of Minimal Hepatic Encephalopathy: a Prospective Pilot Study
by: Marta Hernández-Conde, et al.
Published: (2019-01-01)

Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients
by: Crina Fofiu, et al.
Published: (2019-01-01)

Impact of sustained viral response in the evolution of minimal hepatic encephalopathy: A prospective pilot study
by: Marta Hernández-Conde, et al.
Published: (2019-05-01)